We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNTA
251
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$172K 0.01%
+159
New +$1.64K
ZSAN
252
DELISTED
Zosano Pharma Corporation
ZSAN
$170K 0.01%
184
– –
RLYP
253
PUT
DELISTED
RELYPSA INC COM
RLYP
$163K 0.01%
88
-327
-79% -$5.74K
PGNX
254
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$152K 0.01%
361
-1,023
-74% -$4.94K
MCRB icon
255
CALL
Seres Therapeutics
MCRB
$45.9M
$142K 0.01%
+2
New +$1.17K
RGLS
256
DELISTED
Regulus Therapeutics
RGLS
$142K 0.01%
410
-757
-65% -$542K
CLVS
257
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$141K 0.01%
103
+3
+3% +$44
ARLZ
258
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$136K 0.01%
413
+38
+10% +$143
ADXS
259
DELISTED
Advaxis Inc
ADXS
$113K 0.01%
+933
New +$120K
ADXS
260
PUT
DELISTED
Advaxis Inc
ADXS
$113K 0.01%
9
-27
-75% -$3.46K
RXII
261
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$107K 0.01%
2,289
+2,054
+874% +$96K
LUMO
262
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$97K 0.01%
18
-8
-31% -$992
DRRX
263
CALL
DELISTED
DURECT Corp
DRRX
$94K ﹤0.01%
+77
New +$988
TENX icon
264
CALL
Tenax Therapeutics
TENX
$397M
– –
0
– –
ARCT icon
265
Arcturus Therapeutics
ARCT
$160M
$82K ﹤0.01%
2,617
-26,078
-91% -$822K
AKBA icon
266
CALL
Akebia Therapeutics
AKBA
$335M
$75K ﹤0.01%
100
– –
NVIV
267
CALL
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
0
– –
PGNX
268
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$55K ﹤0.01%
130
– –
ADYX
269
CALL
DELISTED
Adynxx Inc
ADYX
$54K ﹤0.01%
8
– –
RXII
270
DELISTED
GALENA BIOPHARMA INC COM
RXII
$53K ﹤0.01%
+113,530
New +$53K
FOCL
271
PUT
EDAP TMS S.A.
FOCL
$228M
$52K ﹤0.01%
157
-861
-85% -$2.98K
VKTXW
272
DELISTED
Viking Therapeutics, Inc.
VKTXW
$51K ﹤0.01%
+176,113
New +$65.9K
ATHX
273
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$49K ﹤0.01%
+9
New +$510
NWBO
274
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$47K ﹤0.01%
813
– –
TENX icon
275
PUT
Tenax Therapeutics
TENX
$397M
– –
0
– –
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.